Some genetic profiles show enhanced weight loss from tirzepatide (up to 25-30% body weight reduction), while others may achieve 10-15% reduction despite identical dosing
Lightening, darkening, warming or cooling a shade becomes simple
Here is how GLP-1 options compare, according to clinical trials: Daily oral semaglutide (Wegovy): Average weight loss of 13.6 percent of body weight after about 15 months of treatment, compared with 2.2 percent in a placebo group Average weight loss of 11.2 percent of body weight after 72 weeks of treatment, compared with 2.1 percent in the placebo group
One capsule daily, taken in the morning
As a Hyaluronic Acid derivative, it has a well-tolerated profile and suits most skin types
These include: Large disc extrusions or sequestered fragments requiring surgical intervention Severe spinal stenosis with significant canal narrowing Bone spurs (osteophytes) compressing nerve structures Advanced degenerative disc disease with complete disc height loss Spondylolisthesis (vertebral slippage) beyond grade 1 Cauda equina syndrome (medical emergency requiring immediate surgery) Users with these conditions typically report minimal improvement from peptide therapy alone